Vimta Labs Limited
Quality (79/100) does the heavy lifting; momentum (36/100) is the drag.
Fair valueStocksWizard rates Vimta Labs Limited a Buy, scoring 62/100 on our blended model. At ₹599.3 it trades below our blended DCF and relative-multiples fair value of ₹683.87, about 14% upside to that estimate — we read it as fairly valued. On 32.4x trailing earnings it sits cheaper than the Healthcare median of about 37.4x. The price is about 20% below its 52-week high of ₹747.99 and 58% above the low of ₹379.3. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 7/9. It clears 9 of 12 investability checks, with durability 79, valuation 59 and momentum 36 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹547.09.
1-year price
EOD · 2026-09-2552-week range
-19.88% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Buy62Piotroski F-score 7/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- No data: ROE above 15%
- Pass: Low debt (D/E < 0.5): 0.01x
- Pass: Positive free cash flow
- Pass: Revenue growth > 10%: 12%
- Pass: Earnings growing: 11%
- Pass: Net margin ≥ 10%: 18.9%
- No data: Current ratio > 1.5
- Pass: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Fail: Above 50-day average
- Fail: Positive 1-year return
- Pass: Altman Z in safe zone: Z 15.74
- Pass: Piotroski ≥ 7: 7/9
Shareholding
- Promoter65.9%
- Institutions4.3%
- Public & other29.8%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Healthy profit margin (18.9%).
- Financially solid — Altman Z 15.74.
- High Piotroski quality score (7/9).
Bear case
Weaknesses
- Down 20% over the past year.
About Vimta Labs Limited
Vimta Labs Limited provides contract research and testing services to biopharmaceutical, medical device, agrochemical, and specialty chemical companies across India and international markets. The company offers preclinical and clinical research, drug discovery and development services, drug life cycle management support, and analytical services for the pharmaceutical sector, alongside preclinical testing for medical device manufacturers.
Vimta Labs Limited — frequently asked questions
Is Vimta Labs Limited a buy, hold or sell?
StocksWizard currently rates Vimta Labs Limited (VIMTALABS) a Buy, based on a blended score of 62/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Vimta Labs Limited's fair value?
Our blended DCF and relative-valuation model estimates Vimta Labs Limited's fair value at about ₹683.87, versus a current price of ₹599.3 — roughly 14% upside. On that basis the stock looks fairly valued.
Is Vimta Labs Limited financially healthy?
Vimta Labs Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 7/9.
How has Vimta Labs Limited's share price performed?
Vimta Labs Limited is down 20% over the past year and up 2% over three months, and last traded at ₹599.3. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.